Black Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate Update
GlobeNewswire · 财报与经营业绩 · November 10, 2026 at 6:30 AM ET
Read the full report at the original publisher.